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Elazig, TurkeyABSTRACTBackground: Following maternal administration, local anesthetics pass into breast milk. In the present study, we aimed to com-
pare the passage of levobupivacaine and bupivacaine into breast milk following epidural anesthesia for cesarean delivery.
Methods: A total of 20 women undergoing elective cesarean delivery under epidural anesthesia were randomized to receive either
0.5% levobupivacaine or 0.5% racemic bupivacaine via an epidural catheter. Immediately before and 30 min, 1 h, 2 h, 6 h, 12 h and
24 h after administration of epidural local anesthetic, maternal blood and breast milk samples were taken simultaneously. Drug
concentrations in plasma and milk were determined via high-performance liquid chromatography. The infant’s drug exposure was
determined by calculating milk/plasma ratios of levobupivacaine and bupivacaine.
Results: Both levobupivacaine and bupivacaine were detected in breast milk 30 min after epidural administration. Concentrations
of both agents showed constant and similar decreases in milk and plasma and were nearly undetectable at 24 h. The milk/plasma
ratios were 0.34 ± 0.13 for levobupivacaine and 0.37 ± 0.14 for bupivacaine.
Conclusions: Both levobupivacaine and bupivacaine pass into breast milk following epidural administration. The concentration of
both drugs was approximately three times lower in breast milk than in maternal plasma.c 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).
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Although it is recommended that infants are fed breast
milk for at least the ﬁrst six months of life,1,2 some med-
ications used by mothers during labor or breastfeeding
can pass into breast milk and may be potential harmful
to the infant.3,4 Previous studies have shown that local
anesthetics, such as racemic bupivacaine, lidocaine and
ropivacaine pass into breast milk,5–7 although it has
been suggested that the use of bupivacaine for epidural
anesthesia is safe with regard to breastfeeding.5 To our
knowledge, levobupivacaine transfer into human breast
milk has not been studied. Therefore, we aimed to inves-
tigate the degree to which levobupivacaine passes into
breast milk following epidural anesthesia for elective
cesarean delivery.Accepted March 2014
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E-mail address: abestas@ﬁrat.edu.trTransfer of medications into breast milk depends on
pharmacological properties such as protein binding and
lipid solubility, lower protein binding being associated
with greater transfer.3 Because protein binding of
levobupivacaine (97%) is more than that of racemic bupiv-
acaine (95%), we considered it might undergo less transfer
into breast milk. Therefore, we also compared the mater-
nal plasma and milk concentrations of both drugs.Methods
The study was approved by the Firat University School
of Medicine Clinical Research Ethics Committee, and
written informed consent was obtained from all partici-
pants. Twenty American Society of Anesthesiologists
physical status I or II parturients aged 18–40 years with
singleton uncomplicated full-term pregnancy undergo-
ing elective cesarean delivery under epidural anesthesia
were included in this prospective, randomized, double-
blind study. Exclusion criteria were obstetric problems
218 Levobupivacaine and breast milk(fetal anomaly, fetal growth restriction, fetal distress,
preeclampsia, eclampsia, Rh incompatibility or congen-
ital malformations), cardiac, renal or metabolic disor-
ders, allergy or sensitivity to local anesthetics and use
of medications known to affect the metabolism of
levobupivacaine and bupivacaine. All participants
underwent pre-anesthetic examination one day before
surgery.
Participants were randomized to one of two groups,
by using a random number table, to receive either 0.5%
bupivacaine (Group B, n = 10) or 0.5% levobupivacaine
(Group L, n = 10). Parturients were blinded to random-
ization. Each woman received intravenous famotidine
40 mg and metoclopramide 10 mg, 30–45 min before
induction of epidural anesthesia. In the operating room,
electrocardiogram, heart rate, non-invasive arterial
blood pressure and peripheral oxygen saturation
(SpO2) were continuously monitored. An 18-gauge
venous catheter was inserted into the dorsum of one
hand and lactated Ringer’s solution 10 mL/kg was
administered over 30 min before epidural anesthesia.
An 18-gauge venous catheter was inserted into the dor-
sum of the other hand for blood sampling.
An epidural catheter was inserted at the L3–4 verte-
bral level. The epidural space was identiﬁed using loss-
of-resistance to saline with an 18-gauge Tuohy needle.
After a test dose of 2% lidocaine 3 mL, 0.5% levobupiva-
caine (Chirocaine, Abbott, Elverum, Norway) was
administered to parturients in Group L, and 0.5%
racemic bupivacaine (Marcaine AstraZeneca, Istanbul,
Turkey) to those in Group B. The study drugs were
given as fractionated doses (initial dose 5 mL and fur-
ther 5 mL increments as required to a maximum of
150 mg) via the epidural catheter until a sensory block
extending to T6 to pinprick was achieved. Motor block
was evaluated by using a modiﬁed Bromage scale (1: no
block, ability to move feet and legs; 2: ability to move
feet and knees and inability to ﬂex hip; 3: ability to move
feet only; 4: complete block, inability to move feet and
legs). The beginning of the administration of study med-
ications was considered time 0 for evaluation of both
sensory and motor blockade. When a T6 sensory block
was achieved, surgery was allowed to start. If adequate
epidural anesthesia was not achieved, general anesthesia
was administered and these parturients were excluded
from subsequent analysis. Both sensory and motor
block assessments were conducted by a researcher
blinded to group allocation. The total amount of local
anesthetic required and the duration of sensory and
motor blockade were recorded.
Immediately before and 30 min, 1 h, 2 h, 6 h, 12 h
and 24 h after administration of epidural drugs, 2 mL
samples of maternal blood and 2 mL samples of breast
milk were taken simultaneously. Breast milk samples
were collected with a milking pump (Pump-egnell,
Ameda AG, Zug, Switzerland). Blood samples were cen-
trifuged immediately after collection and the plasmaextracted. Plasma and milk samples were stored at
20C until analyses. Quantiﬁcation of levobupivacaine
and racemic bupivacaine was performed using high-per-
formance liquid chromatography (HPLC; HP Agilent
1100, Germany) with ﬂuorescence detection, using the
method described by Papini et al.8 An HPLC C18
column (250 mm · 4.6 mm · 5 lm) was used as the sta-
tionary phase, and a mixture of acetonitrile methanol–
water was used as the mobile phase. Levobupivacaine
and bupivacaine solutions were prepared at methanol
concentrations of 0.2, 0.4, 0.8, 1.6 and 2.4 lg/mL. The
lower limit of detection was 5 ng/mL and values for
intra-assay and inter-assay coefﬁcients of variation were
9.5% and 4.9%, respectively.
Statistical analysis
Data are presented as median or mean ± standard
deviation (SD) as appropriate. Data were analyzed
using the Mann–Whitney U test, the chi-square test
and the Wilcoxon signed-rank test using SPSS version
15.0 (IBM SPSS Inc., Chicago, IL, USA). Values of
P < 0.05 were considered statistically signiﬁcant. For
analysis of concentrations of drugs in plasma and breast
milk, the area under the concentration–time curve from
time 0 to time 24 h (AUC0–24) was calculated using the
trapezoidal rule using SigmaPlot version 8.0 (Systat
Software Inc., Chicago, IL, USA). The two enantiomers
of bupivacaine were measured separately, then
summed. The milk/plasma (M/P) ratio for levobupiva-
caine and bupivacaine was calculated with the following
formula:
M=P ratio ¼ Milk AUC0–24 ððlg=mLÞ  hÞ
=Maternal plasma AUC0–24 ððlg=mLÞ  hÞ
A power calculation for sample size was not performed
as the primary aim of the study was to establish transfer
of the study drugs into breast milk.
Results
Patient characteristics were similar between groups
(Table 1). Epidural anesthesia was adequate in all
patients and general anesthesia was not administered to
any patient. There were no differences between groups
in the characteristics of epidural anesthesia (Table 2).
Nausea was observed in two patients in Group L and
two patients in Group B; nausea and vomiting was
observed in one patient in Group B.
Levobupivacaine was detected in both maternal
plasma and breast milk 30 min after epidural adminis-
tration. However, concentrations of levobupivacaine in
breast milk were approximately three times lower than
those in plasma. Plasma and milk concentrations of
levobupivacaine showed constant and similar declines
and were nearly undetectable 24 h after drug administra-
tion. The two enantiomers of racemic bupivacaine,
Fig. 1 Mean maternal plasma and breast milk levobupiva-
caine concentration versus time. Period 1: immediately before
drug administration. Periods 2, 3, 4, 5, 6 and 7: 30 min, 1, 2, 6,
12 and 24 h after drug administration.
Table 3 Plasma and breast milk concentrations of levobupivacaine and bupivacaine
Plasma AUC0–24
((lg/mL)Æh)
Milk AUC0–24
((lg/mL)Æh)
Milk/plasma ratio
Levobupivacaine 5.17 ± 0.98 1.71 ± 0.65 0.34 ± 0.13
Bupivacaine (total) 4.79 ± 1.90 1.73 ± 0.93 0.37 ± 0.14
S()-bupivacaine 2.60 ± 0.98 0.85 ± 0.62 0.32 ± 0.21
R(+)-bupivacaine 2.19 ± 0.93 0.88 ± 0.36 0.44 ± 0.19
Values are mean ± SD. AUC0–24: area under the concentration–time curve from 0 to 24 h.
Table 2 Characteristics of epidural anesthesia
Group L
(n = 10)
Group B
(n = 10)
Total dose of local anesthetic (mg) 80.0 ± 10.5 82.5 ± 12.1
Time to achieve T6 block (min) 16.3 ± 3.0 15.3 ± 3.4
Maximum modiﬁed Bromage scale score 3 3
Duration of sensory block (min) 320 ± 59 332 ± 68
Duration of motor block (min) 142 ± 90 135 ± 105
Data are mean ± SD or number.
Table 1 Patient characteristics
Group L
(n = 10)
Group B
(n = 10)
Age (years) 25.9 ± 7.0 28.8 ± 6.1
Weight (kg) 69.6 ± 9.4 71.5 ± 2.9
Height (cm) 160 ± 6.4 159 ± 4.1
ASA Physical Status Class I/II 9/1 8/2
Data are mean ± SD or number. ASA: American Society of Anesthesiologists.
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detected in both maternal plasma and breast milk
30 min after epidural administration. The course of both
plasma and breast milk concentrations of bupivacaine
was similar to that of levobupivacaine. As with levobup-
ivacaine, the concentrations of racemic bupivacaine in
breast milk were almost one-third of those in maternal
plasma (Table 3). The proﬁles of plasma and breast milk
concentrations versus time for levobupivacaine and
bupivacaine are shown in Figs. 1 and 2, respectively.
There were no signiﬁcant differences between the mean
concentrations of levobupivacaine and bupivacaine in
either plasma or breast milk at all evaluation points.
In addition, no signiﬁcant difference in AUC0–24 for
both drugs was found. M/P ratios based on AUC0–24
values were 0.34 ± 0.13 and 0.37 ± 0.14 for levobupiva-
caine and racemic bupivacaine, respectively. There was
no signiﬁcant difference in M/P ratios between the two
groups.Discussion
This study demonstrated that levobupivacaine, like race-
mic bupivacaine, passes into breast milk. The concentra-
tion of levobupivacaine was approximately three timeslower in breast milk than in plasma. The amount of both
drugs in plasma and breast milk continuously decreased
and was nearly undetectable 24 h after administration.
Previous studies have shown that bupivacaine is trans-
ferred into breast milk,5,6 but to our knowledge this is
the ﬁrst report showing that levobupivacaine also passes
into breast milk.
Fig. 2 Mean maternal plasma and breast milk racemic
bupivacaine concentration versus time. Period 1: immediately
before drug administration. Periods 2, 3, 4, 5, 6 and 7: 30 min,
1, 2, 6, 12 and 24 h after drug administration.
220 Levobupivacaine and breast milkAlthough breast milk is an optimal food for infants,
transmission of medicines used by the mother to breast
milk can potentially cause adverse effects in infants.
Therefore, when a new medicine is given to a nursing
mother, there is concern about exposure through milk.
It has been suggested that medications can be easily
transferred to milk, especially during the ﬁrst two weeks
postpartum because gaps between mammary cells are
not yet closed during that period.4 It is, therefore,
important to know whether anesthetics and/or analge-
sics administered to the parturient during delivery are
transferred to breast milk. Previous studies have shown
that some local anesthetics can be transferred to breast
milk.5,7,9 In the present study, we have demonstrated
that levobupivacaine also passes into breast milk.
The passage of drugs into breast milk usually occurs
via passive diffusion proportional to the concentration
of drug in maternal plasma. In addition, physicochemi-
cal characteristics such as molecular weight, lipid solu-
bility, protein-binding and pKa are important.
4,10 High
rates of transfer of levobupivacaine to breast milk may
be expected because of its low molecular weight, lipo-
philicity, weak basic structure and ease of transport to
the central nervous system.11 However, in the present
study, levobupivacaine was detected in breast milk at
approximately one-third of the concentration in mater-
nal plasma. This might be because levobupivacaine is
97% bound to plasma proteins, especially a1-acid glyco-
protein. Only non-ionized portions of compounds that
are not bound to plasma proteins can be transferred to
breast milk.
It is also important to quantify infant drug exposure,
for which M/P ratio is the most commonly used param-
eter. This can be calculated using several formulae.12
Ortega et al.5 reported the M/P ratio for bupivacaine
as 0.34 for women undergoing cesarean delivery, whichwas dependent on the AUC0–12 values for bupivacaine
when administered epidurally. In our study, the M/P
ratio was calculated via a formula dependent on
AUC0–24 values. We found levobupivacaine and bupiv-
acaine M/P ratios were <1 (0.34 and 0.36, respectively),
statistically indistinguishable from each other, and con-
sistent with the ﬁndings of Ortega.5
Santos et al.13 administered levobupivacaine, racemic
bupivacaine and ropivacaine to pregnant ewes intrave-
nously. Following administration, they detected these
drugs in fetal plasma and tissues. Bader et al.14 adminis-
tered levobupivacaine and bupivacaine epidurally to
women undergoing elective cesarean delivery. They
determined that concentrations of these two drugs in
umbilical venous blood samples taken during delivery
were one-third lower than those in the maternal plasma.
These two studies demonstrate that both levobupiva-
caine and bupivacaine cross the placenta to the fetus.
Therefore, it should be taken into account that, in
addition to breast milk, infants are exposed to local
anesthetic drugs via the placental pathway.
In conclusion, both levobupivacaine and racemic
bupivacaine pass into breast milk following epidural
administration. In both groups, maternal plasma and
milk concentration–time proﬁles were similar.
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